DE69421280T2 - Therapeutisches agens - Google Patents
Therapeutisches agensInfo
- Publication number
- DE69421280T2 DE69421280T2 DE69421280T DE69421280T DE69421280T2 DE 69421280 T2 DE69421280 T2 DE 69421280T2 DE 69421280 T DE69421280 T DE 69421280T DE 69421280 T DE69421280 T DE 69421280T DE 69421280 T2 DE69421280 T2 DE 69421280T2
- Authority
- DE
- Germany
- Prior art keywords
- pain
- extract
- peak
- seed
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000001387 apium graveolens Substances 0.000 claims abstract description 22
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 240000007087 Apium graveolens Species 0.000 claims abstract description 18
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Sedanolide Chemical compound C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 claims abstract description 18
- 235000010591 Appio Nutrition 0.000 claims abstract description 17
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 16
- 239000000945 filler Substances 0.000 claims abstract description 10
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 229950005197 butylphthalide Drugs 0.000 claims abstract description 7
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims abstract description 4
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims abstract description 4
- 229940038472 dicalcium phosphate Drugs 0.000 claims abstract description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- 239000000284 extract Substances 0.000 claims description 57
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 101000878457 Macrocallista nimbosa FMRFamide Chemical group 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 239000011236 particulate material Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 abstract description 19
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 241000208173 Apiaceae Species 0.000 abstract description 5
- 235000004626 essential fatty acids Nutrition 0.000 abstract description 4
- 230000003278 mimic effect Effects 0.000 abstract description 4
- 235000011197 perejil Nutrition 0.000 abstract description 4
- 239000000419 plant extract Substances 0.000 abstract description 4
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 abstract description 2
- 230000006461 physiological response Effects 0.000 abstract description 2
- 240000000662 Anethum graveolens Species 0.000 abstract 2
- 239000001264 anethum graveolens Substances 0.000 abstract 2
- 235000007227 Anethum graveolens Nutrition 0.000 abstract 1
- 235000017311 Anethum sowa Nutrition 0.000 abstract 1
- 235000002764 Apium graveolens Nutrition 0.000 abstract 1
- 240000009164 Petroselinum crispum Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 140
- 230000036407 pain Effects 0.000 description 139
- 239000000469 ethanolic extract Substances 0.000 description 40
- 230000007423 decrease Effects 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 208000025747 Rheumatic disease Diseases 0.000 description 19
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 17
- 206010003246 arthritis Diseases 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 201000005569 Gout Diseases 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 230000000552 rheumatic effect Effects 0.000 description 11
- 230000009102 absorption Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 8
- 238000002798 spectrophotometry method Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 238000004566 IR spectroscopy Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000010685 fatty oil Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000012675 alcoholic extract Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 238000003705 background correction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000208317 Petroselinum Species 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 229940116732 celery seed extract Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000002849 chondrocalcinosis Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002066 eicosanoids Chemical class 0.000 description 3
- 238000013213 extrapolation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010003274 Arthritis viral Diseases 0.000 description 2
- 208000000003 Breakthrough pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- -1 gold salts Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000153885 Appio Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 1
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002266 menstruation inducing agent Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229940072647 panadol Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003131 sacroiliac joint Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPL960593 | 1993-06-25 | ||
| PCT/AU1994/000342 WO1995000157A1 (en) | 1993-06-25 | 1994-06-24 | Therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69421280D1 DE69421280D1 (de) | 1999-11-25 |
| DE69421280T2 true DE69421280T2 (de) | 2000-07-13 |
Family
ID=3777003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69421280T Expired - Fee Related DE69421280T2 (de) | 1993-06-25 | 1994-06-24 | Therapeutisches agens |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0708651B1 (https=) |
| JP (1) | JPH09505024A (https=) |
| CN (1) | CN1129908A (https=) |
| AT (1) | ATE185698T1 (https=) |
| CA (1) | CA2165794A1 (https=) |
| DE (1) | DE69421280T2 (https=) |
| ES (1) | ES2140541T3 (https=) |
| IN (1) | IN178310B (https=) |
| NZ (1) | NZ267567A (https=) |
| PL (1) | PL176595B1 (https=) |
| WO (1) | WO1995000157A1 (https=) |
| ZA (1) | ZA944568B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9821670D0 (en) * | 1998-10-05 | 1998-12-02 | Muhlbauer Roman C | Plant extracts for the treatment of increased bone resorption |
| AUPP797598A0 (en) * | 1998-12-30 | 1999-01-28 | Butters, Desley | Therapeutic agent |
| US6352728B1 (en) * | 1999-11-02 | 2002-03-05 | International Celery Development Alliance Pty. Ltd. | Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation |
| GB0211943D0 (en) * | 2002-05-23 | 2002-07-03 | Univ Sheffield | Anti-helicobacter activity of celery seed components |
| JP4804353B2 (ja) * | 2003-05-14 | 2011-11-02 | ディーエスエム アイピー アセッツ ビー．ブイ． | 糖尿病の治療及び予防のためのフタリド誘導体の使用 |
| EP1662906A1 (en) | 2003-09-23 | 2006-06-07 | DSM IP Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
| CN1257711C (zh) | 2003-12-05 | 2006-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 丁苯酞软胶囊及其制备工艺 |
| ES2375302T3 (es) * | 2005-05-24 | 2012-02-28 | Dsm Ip Assets B.V. | Derivados de ligustilida para el tratamiento de trastornos inflamatorios. |
| KR20090078777A (ko) * | 2006-08-11 | 2009-07-20 | 디에스엠 아이피 어셋츠 비.브이. | 중추 신경계 질환의 치료를 위한 리구스틸라이드 유도체 |
| CN100569241C (zh) * | 2007-01-17 | 2009-12-16 | 北京天川军威医药技术开发有限公司 | 芹菜籽乙酸乙酯萃取物及其用途 |
| US8722338B2 (en) | 2009-03-11 | 2014-05-13 | The Johns Hopkins University | Modulation of ABCG2-mediated urate transport to treat hyperuricemia and gout |
| AU2010329604B2 (en) * | 2009-11-23 | 2016-05-19 | Bagi Research Limited | Novel therapeutic methods for treating inflammation and immune system disorders |
| JP5581120B2 (ja) * | 2010-06-07 | 2014-08-27 | 花王株式会社 | 電位依存性カチオンチャネル抑制剤 |
| CN102697772A (zh) * | 2012-05-08 | 2012-10-03 | 中国人民解放军第二军医大学 | 一种治疗痛风的药物组合物及其应用 |
| CN103183654B (zh) * | 2013-01-30 | 2014-11-05 | 泰山医学院 | 芹菜籽活性单体的分离纯化制备工艺 |
| CN105535116A (zh) * | 2015-12-23 | 2016-05-04 | 辽宁科技学院 | 一种天然药物提取物及其制备方法 |
| CN110582480B (zh) | 2017-04-21 | 2023-11-10 | 塔斯马尼亚大学 | 治疗化合物和方法 |
| KR20210133463A (ko) * | 2020-04-29 | 2021-11-08 | 한국 한의학 연구원 | 시라 추출물을 유효성분으로 함유하는 골질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2334368A1 (fr) * | 1975-12-10 | 1977-07-08 | Unilever Nv | Procede d'isolation, a partir des pepins de raisin, d'une substance a activite anti-inflammatoire, et composition pour la peau, contenant une telle substance |
| DE3040246C2 (de) * | 1979-10-29 | 1985-01-10 | Osaka Chemical Laboratory Co., Ltd., Osaka | Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung |
| DE3347658A1 (de) * | 1983-12-31 | 1985-07-11 | Troponwerke GmbH & Co KG, 5000 Köln | 1.4-naphthochinonderivate mit entzuendungshemmender wirkung |
| JPS61257155A (ja) * | 1985-05-10 | 1986-11-14 | Horiuchi:Kk | 抗酸化食品 |
| JPS63501288A (ja) * | 1985-09-20 | 1988-05-19 | ジ・アップジョン・カンパニ− | １，４−ナフタレンジオ−ルおよび１，４−ヒドロキノン誘導体 |
| US4753935A (en) * | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
| FR2611502B1 (fr) * | 1987-02-24 | 1990-03-09 | Natura Medica Laboratoires | Extrait de racines d'ombellifere obtenu par extraction hydroalcoolique, procede de preparation d'un tel extrait; et composition therapeutique, notamment a activite diuretique, cardiovasculaire, antalgique ou anti-inflammatoire comprenant un tel extrait |
| JPH02196767A (ja) * | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | ヒドロキサム酸誘導体 |
| US5102883A (en) * | 1989-10-31 | 1992-04-07 | Du Pont Merck Pharmaceutical Company | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents |
| IT1242020B (it) * | 1990-11-20 | 1994-02-02 | Sigma Tau Ind Farmaceuti | Ftalidilidene derivati della carnitina e di alcanoil carnitine e composizioni farmaceutiche che li contengono. |
| AU653024B2 (en) * | 1991-05-30 | 1994-09-15 | Novartis Ag | Substituted diaminophthalimides and analogues |
-
1994
- 1994-06-24 IN IN492CA1994 patent/IN178310B/en unknown
- 1994-06-24 WO PCT/AU1994/000342 patent/WO1995000157A1/en not_active Ceased
- 1994-06-24 PL PL94312714A patent/PL176595B1/pl unknown
- 1994-06-24 CA CA002165794A patent/CA2165794A1/en not_active Abandoned
- 1994-06-24 EP EP94918690A patent/EP0708651B1/en not_active Expired - Lifetime
- 1994-06-24 ZA ZA944568A patent/ZA944568B/xx unknown
- 1994-06-24 JP JP6522513A patent/JPH09505024A/ja active Pending
- 1994-06-24 ES ES94918690T patent/ES2140541T3/es not_active Expired - Lifetime
- 1994-06-24 NZ NZ267567A patent/NZ267567A/en unknown
- 1994-06-24 DE DE69421280T patent/DE69421280T2/de not_active Expired - Fee Related
- 1994-06-24 CN CN94193176A patent/CN1129908A/zh active Pending
- 1994-06-24 AT AT94918690T patent/ATE185698T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA944568B (en) | 1995-03-20 |
| JPH09505024A (ja) | 1997-05-20 |
| IN178310B (https=) | 1997-03-22 |
| PL312714A1 (en) | 1996-05-13 |
| PL176595B1 (pl) | 1999-06-30 |
| EP0708651A1 (en) | 1996-05-01 |
| ATE185698T1 (de) | 1999-11-15 |
| NZ267567A (en) | 1997-10-24 |
| CN1129908A (zh) | 1996-08-28 |
| DE69421280D1 (de) | 1999-11-25 |
| EP0708651A4 (en) | 1998-03-04 |
| WO1995000157A1 (en) | 1995-01-05 |
| CA2165794A1 (en) | 1995-01-05 |
| EP0708651B1 (en) | 1999-10-20 |
| ES2140541T3 (es) | 2000-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69421280T2 (de) | Therapeutisches agens | |
| DE602004012745T2 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
| DE2721831A1 (de) | Entzuendungshemmende, topisch anzuwendende arzneipraeparate | |
| DE68904922T2 (de) | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. | |
| DE69619052T2 (de) | Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung | |
| DE69209414T2 (de) | Hirnaktivitätfördernde Zubereitungen | |
| EP0912189A1 (de) | Verwendung von artischocken-(cynara)-extrakten | |
| DE3784695T2 (de) | Gebrauch von Gramineenextrakten als Arzneimittel. | |
| DE212016000151U1 (de) | Zusammensetzung mit Mangostanrindenextrakt zur Behandlung von Hautkrankheiten | |
| DE3024623A1 (de) | Mittel fuer aeusserliche anwendung auf der grundlage von kolostrum | |
| CH669523A5 (https=) | ||
| DE69734163T2 (de) | Kiefernnadelextrakt sowie dessen verwendung | |
| DE112009005041T5 (de) | Verfahren der Extraktzubereitung aus Longankern und die Anwendung des Longankernextrakts | |
| DE3319282A1 (de) | Verwendung von adenosin bei der behandlung von herpes | |
| DE69713596T2 (de) | Antipsoriatische zusammensetzungen enthaltend einen extrakt von asphodelus, verfahren zur herstellung und verwendung | |
| DE60206270T2 (de) | Zusammensetzungen enthaltend thylakoids zur modulierung der entzündung | |
| DE60030786T2 (de) | Murraya koenigii-extrakte zur behandlung von asthma | |
| DE102017105036A1 (de) | Mittel zur Anwendung bei der Behandlung der Dyslipidämie | |
| DE4429735C2 (de) | Pflanzlicher Redoxkatalysator, Mittel zur Behandlung immunbiologischer Zellbelastungsschwächen und Verfahren zu dessen Herstellung | |
| DE2015877C3 (de) | Arzneimittel zur Behandlung der Prostatahypertrophie | |
| WO1991008750A1 (de) | Verwendung von pflanzenteilen der naturpflanze tinospora | |
| EP3299026A1 (de) | Extrakte aus samen von aframomum-arten und deren verwendung | |
| DE202016106651U1 (de) | Entzündungshemmende Komposition aus Cannabidiol und Betulin | |
| EP1210945B1 (de) | Arzneimittelzubereitung mit antiarteriosklerotischer Wirkung | |
| CH690023A5 (de) | Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |